ABT-267
|
1258226-87-7
|
- CAS №
- 1258226-87-7
- английское имя:
- ABT-267
- Синонимы:
- Ontave;ABT-267;ombitasvir;Mr. He wei;Viekira Pak);ABT-267/Ombitasvir;Ombitasvir(ABT-267);Ombitasvir, Paritaprevir, and Ritonavir;2,2'-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide;L-Prolinamide, 2,2'-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
- CBNumber:
- CB02716109
- Формула:
- C50H67N7O8
- молекулярный вес:
- 894.11
- MOL File:
- 1258226-87-7.mol
|
ABT-267 атрибут
| Температура плавления: |
>177°C (dec.) |
| Температура кипения: |
1065.6±65.0 °C(Predicted) |
| плотность: |
1.223±0.06 g/cm3(Predicted) |
| температура хранения: |
-20°C Freezer, Under inert atmosphere |
| растворимость: |
ДМСО (Мало растворим), метанол (Мало растворим) |
| пка: |
10.92±0.46(Predicted) |
| форма: |
Твердый |
| цвет: |
От белоснежного до бледно-бежевого |
| FDA UNII: |
2302768XJ8 |
безопасность
- Заявления о рисках и безопасности
- код информации об опасности(GHS)
ABT-267 химические свойства, назначение, производство
Описание
Ombitasvir hydrate is a NS5A non-nucleoside polymerase inhibitor
which is approved as part of a four drug combination for the
treatment of adults with genotype 1 hepatitis C virus infection
including those with compensated cirrhosis. The four drug
combination treatment consists of ombitasvir, paritaprevir
(XXVII), ritonavir, and dasabuvir (X). This combination treatment
is marketed as Viekira Pak and was developed by Abbvie as an
all oral treatment that eliminates the need for pegylated interferon-
a injections.
Использование
Ombitasvir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
Определение
ChEBI: A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.
Ферментативный ингибитор
This N-phenylpyrrolidine-based, pan-genotypic HCV NS5A protease inhibitor (FW = 893.14 g/mol), also named ABT-267, targets Nonstructural protein 5A (NS5A), a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication.Ombitasvir exhibits low-picomolar EC50 values against Hepatitis C virus, with superior pharmacokinetics. Although ombitasvir shows a low barrier to resistance, when given as monotherapy, co-administration with other antivirals enhances its barrier to resistance. Indeed, a 12-week, Phase- 3 study demonstrated that a multi-targeted regimen consisting of ombitasvir, dasabuvir and ribavirin is highly effective and showed a low rate of treatment discontinuation.
ABT-267 препаратная продукция и сырье
сырьё
препарат
ABT-267 поставщик
Global( 80)Suppliers